President, CNS Cancers US · NovoCure Ltd (NVCR)

Francis Leonard

A named executive officer of NovoCure in every fiscal year CompBrief holds from FY2022 to FY2023. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$5,039,237

Salary $475,000Stock awards $2,866,517

FY2022: $6,125,806

2nd of 3 named executive officers at NovoCure by FY2023 total.

3 named officers on file for NovoCure, FY2023

Francis Leonard’s pay file — $29

  • 2 fiscal years of pay, line by line
  • 9 equity grants, each cited to its filing
  • NVCR’s disclosed peer group of 17 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how NovoCure’s whole pay program stands against its peers

  • NovoCure’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on NVCR→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 22, 2024 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Francis Leonard’s full pay file as a PDF — free

More than this page: up to 10 years of Francis’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Francis Leonard compensation by year

NovoCure Summary Compensation Table · all 2 fiscal years held
In US dollars, as NovoCure reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2022FY2023
Salary$475,000$475,000
Bonus$0$0
Stock awards$3,299,814$2,866,517
Option awards$2,102,893$1,435,196
Non-equity incentive$237,500$253,650
Pension and deferred compensation$0—
All other$10,599$8,874
Total$6,125,806$5,039,237

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: NovoCure Ltd DEF 14A filed April 22, 2024, accession 0001645113-24-000011, and prior-year filings. Open the filing on EDGAR.

How this page was built: the NovoCure Ltd filed document, accession 0001645113-24-000011. Every figure is read from that document and cited to the page and table it appears in. Filed April 22, 2024.

$6.1M
$5.0M
FY22
FY23
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2024 year-end
TypeUnvested unitsValue at year-endExercise price
RSU102,249$3,047,020—
PSU102,249$3,047,020—
PSU18,621$554,906—
PSU17,371$517,656—
RSU12,414$369,937—
RSU5,790$172,542—
RSU2,276$67,825—
Option156,348—$16.30
Option23,228—$76.97
Option5,804—$73.20
Option4,000—$153.09
Option15,210—$80.59

Per the Outstanding Equity Awards at Fiscal Year-End table in NovoCure Ltd's FY2024 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

23 Form 4 lines since the FY2023 proxy (filed April 22, 2024)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-06-30Grant or award—1,905$11.15461,425
2026-06-04Sale—34,273$17.93459,520
2026-03-04Sale—5,607$13.31493,793
2026-03-03Grant or award derivative—216,388$0.00216,388
2026-03-03Grant or award—150,000$0.00499,400
2026-03-02Sale—7,232$13.49349,400
2026-02-28Grant or award—18,621$0.00356,632
2026-02-27Sale—9,734$13.66338,011

The 8 most recent of 23 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

NovoCure’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Ashley CordovaChief Financial Officer$6,317,066
Francis Leonard · this pagePresident, CNS Cancers US$5,039,237
Asaf DanzigerChief Executive Officer$1,521,026

Board service

NovoCure board · FY2025

How this board is paid

Company policy: NovoCure pays directors a $55,000 cash retainer and $375,000 in equity. As stated in NovoCure's FY2025 proxy.

The full NovoCure compensation record

free company brief

This page is one person within NovoCure's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the NovoCure proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are NovoCure's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Francis Leonard's compensation dossier · One-time report. No refunds.